UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________

FORM 10-Q

_______________

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~February~~May 2831, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission File Number: 000-52403

___________________________________________________

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

___________________________________________________

Nevada		46-5644005
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

#3 Bethesda Metro Center, Suite 700 Bethesda, MD		20814
(Address of principal executive offices)		(Zip Code)

(877) 424-2429

(Registrant’s telephone number, including area code)

~~Securities registered under Section 12(b) of the Act:~~____________________________________________________

~~Title~~(Former ofname, ~~each~~former ~~class~~address ~~Name~~and offormer ~~each~~fiscal year, ~~exchange~~if onchanged ~~which~~since ~~registered~~last ~~N/A N/A~~report)

Securities registered under Section 12(g) of the Act:

Common Stock, $.0001 Par Value

(Title of class)

_____________________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~April~~July 14, 2025, the registrant had 492,~~196~~511,~~841~~352 shares of its Common Stock, $0.0001 par value, outstanding.

When used in this quarterly report, the terms “CNBX,” “the Company,” “we,” “our,” and “us” refer to CNBX Pharmaceuticals Inc. and its wholly- owned ~~subsidiary~~subsidiaries, G.R.I.N Ultra Ltd., and Digestix Bioscience Inc.

CNBX PHARMACEUTICALS INC.

FORM 10-Q

~~FEBRUARY~~MAY 2831ST, 2025

INDEX

Cautionary Note Regarding Forward-Looking Statements		3
PART I – FINANCIAL INFORMATION		4
Item 1.	Consolidated Financial Statements	4
	Consolidated Balance Sheets as of February 28, 2025 (unaudited) and August 31, 2024	4
	Consolidated Balance Sheets as of May 31st, 2025 (unaudited) and August 31, 2024	4
	Consolidated Statements of Operations for the Three and Six Months Ended February 28, 2025 and February 29, 2024 (unaudited)	5
	Consolidated Statements of Operations for the Three and Nine Months Ended May 31st, 2025 and 2024 (unaudited)	5
	Consolidated Statements of Stockholder’s Equity for the Three and Six Months Ended February 28, 2025 and February 29, 2024 (unaudited)	6
	Consolidated Statements of Stockholders’ Equity (Deficit) for the Three and Nine Months Ended May 31st, 2025 and 2024 and the Year Ended August 31, 2024	6
	Consolidated Statements of Cash Flows for the Six Months Ended February 28, 2025 and February 29, 2024 (unaudited)	8
	Consolidated Statements of Cash Flows for the Nine Months Ended May 31st, 2025 and 2024 (unaudited)	8
	Notes to Consolidated Financial Statements (unaudited)	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1314
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	1417
Item 4.	Controls and Procedures	1417
PART II – OTHER INFORMATION		1618
Item 1.	Legal ~~Proceeding~~Proceedings	1618
Item 1A.	Risk Factors	1618
Item 2.	Recent Sale of Unregistered Securities	1618
Item 5.	Other Information	1618
Item 6.	Exhibits	1618
SIGNATURE		17
SIGNATURES		19

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

	·	the size and growth of the potential markets for our products and the ability to serve those markets;

	·	our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;

	·	the rate and degree of market acceptance of any of our products;

	·	our expectations regarding competition;

	·	our anticipated growth strategies;

	·	our ability to attract or retain key personnel;

	·	our ability to establish and maintain development partnerships;

	·	regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws;

	·	our ability to obtain and maintain intellectual property protection for our products; and

	·	the anticipated trends and challenges in our business and the market in which we operate.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended August 31, 2024 (filed on November 29th, 2024), entitled “Risk Factors” as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

CNBX PHARMACEUTICALS INC.

Consolidated Balance Sheets

	February 28,			August 31,
	May 31,			August 31,
	2025			2024
	Unaudited			Audited
ASSETS
Current assets:
Cash and cash equivalents	$	4513,~~675~~648		$	26,416
Prepaid expenses and other receivables		4,~~985~~967			4,~~969~~967
Total current assets		5018,~~660~~615			31,~~385~~383
Equipment, net		–			–
Total assets	$	5018,~~660~~615		$	31,~~385~~383
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$	6241,~~943~~239		$	~~217~~40,~~774~~841
Convertible loan		1,~~398~~340,~~781~~136			1,295,107
Due to a related party		1,~~159~~174,~~416~~645			~~998~~1,~~484~~175,415
Total current liabilities		2,~~621~~556,~~140~~020			2,511,~~365~~363
Stockholders' equity (deficit):
Preferred stock, $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding		–			–
Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding		–			–
Common stock, $.0001 par value, 900,000,000 shares authorized, 33,861,352 and 31,111,352 shares issued and outstanding at February 28, 2025 and August 31, 2024, respectively		3,386			3,111
Common stock, $0.0001 par value, 1,800,000,000 and 900,000,000 shares authorized, on May 31, 2025 and August 31, 2024 respectively, 92,511,352 and 31,111,352 shares issued and outstanding on May 31, 2025 and August 31, 2024 respectively		9,251			3,111
Additional paid-in capital		22,~~484~~571,~~674~~611			22,471,309
Issuance of warrants		–			–
Accumulated deficit		(25,118,267	)		(24,954,400	)
Other comprehensive loss		–			–
Total stockholders' equity (deficit)		(2,537,405	)		(2,479,980	)
Accumulated deficit		(25,058,540	)		(24,954,400	)
Total liabilities and stockholders' equity	$	18,615		$	31,383
Total stockholders' equity (deficit)		(2,570,480	)		(2,479,980	)
Total liabilities and stockholders' equity	$	50,660		$	31,385

See accompanying notes to consolidated financial statements.

* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

	For the Three Months Ended						For the ~~Six~~Nine Months Ended
	February 28,			February 29,			February 28,			February 29,
	May 31,			May 31,			May 31,			May 31,
	2025			2024			2025			2024
Revenues
	Unaudited
Services	$	–		$	40,637		$	–		$	130,074
Revenues	$	–		$	–		$	–		$	130,074
Cost of services		–			6,220			–			17,570
Gross Profit		–			34,417			–			112,504
Operating expenses:
Research and development expense		–			~~107~~42,~~199~~884			–			~~208~~268,~~267~~722
General and administrative expenses		6440,~~743~~380			~~133~~109,~~646~~394			~~101~~141,~~580~~960			~~282~~391,~~565~~958
Total operating expenses		6440,~~743~~380			~~240~~152,~~845~~278			~~101~~141,~~580~~960			~~490~~660,~~832~~680
Loss from operations		(6440,~~743~~380	)		(~~206~~152,~~428~~278	)		(~~101~~141,~~580~~960	)		(~~378~~530,~~328~~606	)
Other income (loss)
Other income
Capital loss		–			(123,711	)		–			(123,711	)
Capital Gain (loss)		–			–			–			(88,934	)
Financial income (Loss), net		(5,045	)		4,680			(2,560	)		(1,943	)
Financial Income (loss)		(19,347	)		21,646			(21,907	)		(15,074	)
Net (loss)		(69,788	)		(325,459	)		(104,140	)		(503,982	)
Net loss		(59,727	)		(130,632	)		(163,867	)		(634,614	)
Profit (loss) from available for sale assets		–			–			–			–
Total comprehensive income (loss)	$	(69,788	)	$	(325,459	)	$	(104,140	)	$	(503,982	)
Total comprehensive (income) loss	$	(59,727	)	$	(130,632	)	$	(163,867	)	$	(634,614	)
Net loss per share - basic and diluted:	$	(0.00	)	$	(0.0100	)	$	(0.00	)	$	(0.02	)
Weighted average number of shares outstanding - Basic and Diluted		3242,~~096~~597,~~769~~394			3031,~~988~~111,~~275~~352			3135,~~764~~475,~~667~~271			29,~~374~~964,~~538~~272

See accompanying notes to consolidated financial statements.

* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

CNBX PHARMACEUTICALS INC.

Consolidated Statements of ~~Stockholder’s~~ Stockholders' Equity (Deficit)

(Unaudited)


	Common stock				Additional paid in				Unrealized gain (loss) on available-for sale financial		Accumulated			Total stockholders’ equity
	Shares		Amount		Capital		Warrants		gain		deficit			(deficit)
Balance, August 31, 2024		31,111,352	$	3,111	$	22,471,309	$	–	$	–	$	(24,954,400	)	$	(2,479,980	)

Exercise of a Convertible loan to shares of common stock		61,400,000		6,140		100,302		–		–		–			106,442

Net loss		–		–		–		–		–		(163,867	)		(163,867	)

Balance, May 31, 2025		92,511,352	$	9,251	$	22,571,611	$	–	$	–	$	(25,118,267	)	$	(2,537,405	)

For the six months ended February 28, 2025

	Common stock				Additional paid in				Unrealized gain (loss) on available-for sale financial		Accumulated			Total stockholders’ equity
	Shares		Amount		Capital		Warrants		gain		deficit			(deficit)
Balance, February 28, 2025		33,861,352	$	3,386	$	22,484,674	$	–	$	–	$	(25,058,540	)	$	(2,570,480	)

Exercise of a Convertible loan to shares of common stock		58,650,000		5,865		86,937		–		–		–			92,802

Net Loss		–		–		–		–		–		(59,727	)		(59,727	)

Balance, May 31, 2025		92,511,352	$	9,251	$	22,571,611	$	–	$	–	$	(25,118,267	)	$	(2,537,405	)

	Common Stock				Additional Paid In				Other Comprehensive		Accumulated			Total Stockholders’ Equity
	Shares		Amount		Capital		Warrants		Gain		Deficit			(Deficit)
Balance, August 31, 2024		31,111,352	$	3,111	$	22,471,309	$	–	$	–	$	(24,954,400	)	$	(2,479,980	)
Share based payment		–		–		–		–		–		–			–
Exercise of CLA to shares		2,750,000		275		13,365		–		–		–			13,640
Other comprehensive loss		–		–		–		–		–		–			–
Net loss		–		–		–		–		–		(104,140	)		(104,140	)
Balance, February 28, 2025		33,861,352	$	3,386	$	22,484,674	$	–	$	–	$	(25,058,540	)	$	(2,570,480	)

For the three months ended February 28, 2025

	Common Stock				Additional Paid In				Other Comprehensive		Accumulated			Total Stockholders’ Equity
	Shares		Amount		Capital		Warrants		Gain		Deficit			(Deficit)
Balance, November 30, 2024		31,111,352	$	3,111	$	22,471,309	$	–	$	–	$	(24,988,752	)	$	(2,514,332	)
Share based payment		–		–		–		–		–		–			–
Exercise of CLA to shares		2,750,000		275		13,365		–		–		–			13,640
Other comprehensive loss		–				–		–		–		–			–
Net loss		–		–		–		–		–		(69,788	)		(69,788	)
Balance, February 28, 2025		33,861,352	$	3,386	$	22,484,674	$	–	$	–	$	(25,058,540	)	$	(2,570,480	)

CNBX PHARMACEUTICALS INC.

Consolidated Statements of ~~Stockholder’s~~ Stockholders' Equity (Deficit)

(~~Unaudited~~continued)

For the six months ended February 29, 2024


	Common stock				Additional paid in				Unrealized gain (loss) on available-for sale financial		Accumulated			Total stockholders’ equity
	Shares		Amount		capital		Warrants		gain		deficit			(deficit)
Balance, August 31, 2023		22,611,352	$	2,261	$	22,239,652	$	–	$	–	$	(24,259,202	)	$	(2,017,289	)

Share based payment		–		–		104,745		–		–		–			104,745

Exercise of a Convertible loan to shares of common stock		8,500,000		850		91,937		–		–		–			92,787

Net loss		–		–		–		–		–		(634,614	)		(634,614	)

Balance, May 31, 2024		31,111,352	$	3,111	$	22,436,334	$	–	$	–	$	(24,893,816	)	$	(2,454,371	)

	Common Stock				Additional Paid In				Other Comprehensive		Accumulated			Total Stockholders’ Equity
	Common stock				Additional paid in				Unrealized gain (loss) on available-for sale financial		Accumulated			Total stockholders’ equity
	Shares		Amount		~~Capital~~capital		Warrants		~~Gain~~gain		Deficit			(~~Deficit~~deficit)
Balance, August 31, 2023		22,611,352	$	2,261	$	22,239,652	$	–	$	–	$	(24,259,202	)	$	(2,017,289	)
Balance, February 28, 2024		31,111,352	$	3,111	$	22,401,539	$	–	$	–	$	(24,763,184	)	$	(2,358,534	)
Share based payment		–		–		6934,~~950~~795		–		–		–			6934,~~950~~795
Exercise of CLA to shares		8,500,000		850		91,937		–		–		–			92,787
Net Loss		–		–		–		–		–		(130,632	)		(130,632	)
Net loss		–		–		–		–		–		(503,982	)		(503,982	)
Balance, May 31, 2024		31,111,352	$	3,111	$	22,436,334	$	–	$	–	$	(24,893,816	)	$	(2,454,371	)
Balance, February 29, 2024		31,111,352	$	3,111	$	22,401,539	$	–	$	–	$	(24,763,184	)	$	(2,358,534	)

For the three months ended February 29, 2024

	Common Stock				Additional Paid In				Other Comprehensive		Accumulated			Total Stockholders’ Equity
	Shares		Amount		Capital		Warrants		Gain		Deficit			(Deficit)
Balance, November 30, 2023		28,311,352	$	2,831	$	22,339,965	$	–	$	–	$	(24,437,725	)	$	(2,094,929	)
Share based payment		–		–		34,975		–		–		–			34,975
Exercise of CLA to shares		2,800,000		280		26,599		–		–		–			26,879
Net loss		–		–		–		–		–		(325,459	)		(325,459	)
Balance, February 29, 2024		31,111,352	$	3,111	$	22,401,539	$	–	$	–	$	(24,763,184	)	$	(2,358,534	)

See accompanying notes to consolidated financial statements.

CNBX PHARMACEUTICALS INC.

Consolidated Statements of Cash Flows

(Unaudited)

	For the Six month Ended
	For the Nine Months Ended,
	February 28,			February 29,
	May 31,			May 31,
	2025			2024
Cash flows from operating activities:
Net (Loss)	$	(104,140	)	$	(503,982	)
Net Loss	$	(163,867	)	$	(634,614	)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation		–			72,320
Interest on convertible loans		7,313			16,798
Interest on loans		21,479			16,798
Capital loss		–			123,711
Capital Loss		–			88,934
Changes in operating assets and liabilities:
Share based payment		–			104,745
Share based payment		–			69,950
Accounts Receivable and pre paid expenses		–			87,991
Accounts Receivable and pre-paid expenses		(16	)		(32,163	)
Accounts payable and accrued liabilities		(372	)		67,807
Accounts payable and accrued liabilities		6,102			57,122
Net cash used in operating activities		(142,760	)		(196,019	)
Net cash used in operating activities		(90,741	)		(196,244	)
Cash flows from investing activities:
Sale of equipment		–			114,673
Acquisition of equipment		–			(1,196	)
Realization of equipment		–			20,000
Net cash gain in investing activities		–			113,477
Net cash from (used) in investing activities		–			18,804
Cash flows from financing activities:
Proceeds from convertible loan agreement		110,000			24,993
Convertible loan		129,992			26,252
Net cash provided by financing activities		~~110~~129,~~000~~992			2426,~~993~~252
Effect of exchange rate changes on cash, cash equivalents		–			59,893
Net decrease in cash		(12,768	)		(56,290	)
Net increase (Decrease) in cash		19,259			(92,554	)
Cash and cash equivalents at beginning of the Period		26,416			129,696
Cash and cash equivalents at end of the Period	$	4513,~~675~~648		$	3773,~~142~~406
Significant non-cash transactions:
Exercise of a Convertible loan to shares of common stock.	$	13,640		$	–
Exercise of a Convertible loan to shares of common stock	$	106,442		$	92,787

See accompanying notes to consolidated financial statements.

CNBX PHARMACEUTICALS INC.

Notes to Consolidated Financial Statements

(Unaudited)

Note 1 – Nature of Business, Presentation and Going Concern

Organization

CNBX Pharmaceuticals Inc. (the “Company”), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp.

On September 30, 2010, we increased our authorized capital to 900 million shares of common stock (par value $0.0001) and 100 million shares of preferred stock (par value $0.0001) and effected a 20-for-1 reverse split of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding common stock was reduced from 13,604,000 shares to 680,202 common shares, 100,000,000 preferred shares were unaffected.

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. (“Cannabics”) acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, ~~Cannabics~~CNBX Pharmaceuticals Inc. purchased 41,000,000 shares of the Company’s outstanding restricted common stock for $198,000, representing 51%.

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company’s principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of “CNBX”. Said approval was predicated upon CNBX Pharmaceuticals Inc.’s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. (“GRIN”), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company’s products in Israel.

On July 24, 2017, the Company announced its establishment of a genetics laboratory to develop diagnostic tools based on human genome, tumor genetics and specific cannabinoids.

On August 20, 2020, the Company announced the creation of a new Division for its Anti-Tumor drug candidate RCC-33, for the treatment of colorectal cancer. The emanates from the Company’s focus on a clinical validation path, including in-vivo experiments, collaborations with key medical centers, and the preparation of a product dossier with which the company plans to schedule a Pre IND-Meeting with the US FDA.

On October 18, 2021, the Company filed 2 new Provisional Patent applications on Compositions and Methods for treating cancer, including colorectal cancer and early intervention therapy for colorectal cancer patients.

On February 13, 2022, the company established a Nomination and Governance Committee.

On May 10, 2022, the Company filed a certificate of change (the “Certificate”) with the Secretary of State of the State of Nevada. Pursuant to the Certificate, the Company effectuated a one-for-one hundred twenty (1:120) reverse split of the issued and outstanding shares of common stock of the Company without changing the par value of the stock.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited financial statements should be read in conjunction with our August 31, 2024 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on November ~~29th~~29, 2024.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries GRIN Ultra and Digestix Bioscience Inc. All significant inter-company balances and transactions have been eliminated in consolidation.

Going Concern

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $~~104~~163,~~140~~867 for the ~~six~~nine months ended ~~February~~May 2831, 2025, it has incurred ~~cumulative~~ cumulative losses since inception of $25,~~058~~118,~~540~~267. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

Research and Development Costs

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 “Research and Development” (“ASC 730”). ASC 730 requires that research and development costs be charged to expense when incurred. ~~There were no~~ Research and development costs charged to expense ~~for~~were $0 ~~the~~and ~~six months ended February 28, 2025 compared to~~ $~~208~~268,~~267~~722 for the ~~six~~nine months ended ~~February~~May 2931, 2025 and 2024, respectively.

Reclassifications

Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.

Note 2 – Related Party Transactions

AsDuring ofthe ~~February~~nine 28months ending May 31, 2025, the Company ~~had~~paid ~~One~~$37,087 ~~employee~~in salaries, ~~our~~ ~~Director~~including ~~Eyal~~socials ~~Barad.~~benefits, ~~All~~to ~~employees~~two ~~reside~~directors, incompared ~~Israel~~to $73,732 for the nine months ending May 31, 2024.

During the ~~six~~nine months ending ~~February~~May 2831, 2025~~, the~~ the Company ~~paid~~accrued $~~28,258~~0 in salaries, including socials benefits, to two directors, compared to $50242,~~979~~500 for the ~~six~~nine months ending ~~February 29~~May 31, 2024.

InAs ~~addition,~~of ~~during~~May ~~the six months ending February 28~~31, 2025, the Company ~~accrued~~had $0a balance inoutstanding ~~salaries,~~payable ~~including socials benefits,~~ to two directors,: ~~compared~~Gabriel toYariv ~~accrued~~and ~~expenses~~Eyal ~~of $161,655~~Barad ~~for the six months ending February 29, 2024. During the six months ending February 28, 2025, the Company hasn’t recorded a non-cash expense~~ in ~~share-based payment, to~~ the ~~company~~total ~~chairman,~~of ~~board members and advisor, compared to~~ $69932,~~950 for the~~771 ~~six~~under ~~months~~due ~~ending~~to ~~February~~a ~~29,~~related ~~2024~~party.

AsThe ~~of February 28, 2025, the~~ Company had a balance outstanding ~~payable~~at toMay ~~two~~31, 2025 ~~directors: Gabriel Yariv~~ and ~~Eyal~~at ~~Barad~~May in31, ~~the~~2024 ~~total~~ of $~~932~~223,~~771~~645, ~~under~~payable ~~Accounts~~to ~~payable~~Cannabics, Inc. The advance is due on demand and ~~accrued~~bears ~~liabilities~~no interest.

The Company had a balance outstanding on February 28, 2025 and at February 29, 2024 of $223,645 payable to Cannabics, Inc. The advance is due on demand and bears no interest.

Note 3 – Stockholders’ Equity (Deficit)

Authorized Shares

The Company is authorized to issue up to ~~900~~1,800,000,000 shares of common stock, par value $0.0001 per share. There is also ~~100~~5,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

For the period ending at May 31, 2025, the company issued 61,400,000 shares as a result of a convertible of a loan at a total of $106,442.

Note 4 – Commitments and Contingencies

We no longer lease any properties.

Note 5 – Private Placement of Notes and Warrant

On December 16, 2020, we entered into a Securities Purchase Agreement (“SPA”) with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $2,750,000 to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor’s option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $42 per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company’s Common Stock during the ten (10) consecutive trading days preceding the conversion date (the “notes”). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $42 during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of 18.00%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.

On December 21, 2020, we closed the first tranche and issued a note in the amount of $825,000 (the “Initial Note”). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $550,000 (the “Second Note”). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $1,375,000 (the “Note”). The Initial Note was issued at a discount of $75,000; the Second Note was issued at a discount of $50,000; and the Note was issued at a discount of $125,000. In addition, we issued to the Investor 32,614 shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.

On April 23, 2021, we entered into a senior secured promissory note (the “Senior Secured Note”) for $1,375,000 with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $2,750,000 having an aggregate original issue discount of 10%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to 45,833 shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $60 per share. The warrant may be exercised and converted to Common Stock at the investor’s option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to “accredited investors” within the meaning of Regulation D.

On ~~February~~November 1528, ~~2023~~2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through ~~March~~December 712, 2022, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

On November 28, 2023, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2023, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

On March 16, 2022, we issued to the investor a demand promissory note (the “Demand Note”) in the principal amount of $280,000 (the “Principal”) with an original issue discount of $40,000. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the “Next Subsequent Placement”). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the “Late Charges”). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.

11On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $154,250.00. ($154,000 net of issuance expenses). The Convertible Promissory Note carry interest of 9% and due on June 15, 2023.

WeIn ~~entered~~the ~~into~~period aof ~~forbearance~~January ~~agreements~~through ~~with~~March 2023, the ~~institutional~~Company ~~investor~~entered ~~relating~~into toa ~~that~~Securities ~~certain~~Purchase ~~Senior~~Agreement ~~Secured~~providing ~~Note.~~for ~~Pursuant to~~ the ~~forbearance~~issuance ~~agreement,~~of the ~~investor,~~Convertible ~~through January~~Promissory ~~31,~~Note ~~2025,~~in ~~agreed to forbear from exercising any rights and remedies against~~ the ~~Company~~principal amount ~~related~~of ~~to the outstanding payments and~~$35,000.00. to($35,000 net ~~waive~~of ~~certain~~issuance ~~other~~expenses). ~~defaults~~The ~~under~~Convertible ~~the~~Promissory ~~Senior Secured~~ Note ~~and~~carry ~~related~~interest ~~rights~~of ~~pursuant~~5% toand ~~the~~due ~~registration~~on ~~rights~~June ~~agreement~~15, 2023.

On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $154,250.00. ($154,000 net of issuance expenses). The Convertible Promissory Note carry interest of 9% and due on June 15th 2023.

In the period of January through March 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $35,000.00. ($35,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on June 15th 2023.

On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $65,000.00. ($65,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on August 1, 2023.

On October 13, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $24,993 ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1, 2024.

On September 24, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000 ($30,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1, 2025.

On December 30, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000 ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on April 1, 2025.

On February 3, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $55,000 ($50,000 net of issuance expenses). The Convertible Promissory Note carry interest of 10% and due on October 30, 2025.

~~The~~On ~~Institutional~~April ~~Investor~~24, ~~agreed~~2025, tothe ~~forbear~~Company ~~until~~entered into ~~December~~a ~~12,~~Securities ~~2024~~Purchase ~~from~~Agreement ~~taking~~providing ~~any~~for ~~action~~the ~~against~~issuance of the ~~Company~~Convertible ~~with~~Promissory ~~respect~~Note toin ~~unpaid~~the ~~amounts~~principal ~~owed~~amount ~~and~~of to$20,000 ($20,000 ~~waive~~net ~~certain~~of ~~other~~issuance ~~defaults~~expenses). ~~under the~~The Convertible Promissory Note carry interest of 5% and ~~other~~due ~~rights~~on July 1, 2025.

~~Interest~~The ~~expenses~~Institutional ~~amounted~~Investor agreed to $7forbear until July 1,~~314~~ ~~for~~2025 from taking any action against the ~~six~~Company with respect to unpaid amounts owed and to waive certain other defaults under ~~months~~the ~~ended~~Note ~~February~~and ~~28th,~~other ~~2025~~rights.

~~Note~~Interest 6expenses –amounted ~~Subsequent~~to ~~events~~$21,479 for the nine months ended May 31, 2025.

Note 6 – Subsequent Events

On June 9, 2025, the company issued 9,000,000 shares as a result of a convertible of a loan at a total of $7,017.

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no other such events that warrant disclosure or recognition in the financial statements.

1213

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Company Overview

We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or "window of opportunity" at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company hopes to start first in human Phase I/II clinical trials in ~~2023~~2025. Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.

Results of Operations

For the Three Months Ended ~~February~~May 2831, 2025 and ~~February 29,~~ 2024

Revenues

For the three months ended May 31, 2025 and 2024, there were no incomes.

Operating Expenses

For the three months ended ~~February~~May 2831, 2025, our total operating expenses were $6440,~~743~~380 compared to $~~240~~152,~~845~~278 for the three months ended ~~February~~May 2931, 2024, resulting in a decrease of $~~176~~111,~~102~~898. The decrease is attributable to a ~~total~~ decrease of $6869,~~903~~014 in general administration, and sales and marketing expenses and a decrease of $~~107~~42,~~199~~ 884 in research and development expenses. ~~The~~due ~~decrease~~to isa ~~due~~reduction toin ~~lack~~the ofcompany's ~~funds~~activities.

We ~~incurred~~realized a financial loss of $519,~~045~~347 for the three months ended ~~February~~May 2831st, 2025, compared to ~~other~~ financial ~~Income~~income of $421,~~680~~646 for the three months ended ~~February~~May 2931, 2024. ~~The increase in financial expense was mainly attributable to a capital loss due to a realization of the Company’s Convertible loans.~~

As a result, the net loss was $59,727 for the three months ended May 31st, 2025, compared to a net loss of $130,632 for the three months ended May 31, 2024. The decrease is due to a reduction in the company's activities.

Net Loss

Net loss ~~for the three months ended February 28, 2025~~ was $6959,~~788~~727 compared to net loss $~~325~~130,~~459~~ 632 for the three months ended ~~February~~May 2931st, ~~2024~~2025, for the reasons ~~explained~~noted above.

For the ~~Six~~nine Months Ended ~~February~~May 2831st, 2025 and ~~February 29,~~ 2024

Revenues

For the nine months ended May 31, 2025 there were no incomes compared to $130,074for the nine months ended May 31, 2024. The decrease is due to a reduction in the company's activities.

Operating Expenses

For the ~~six~~nine months ended ~~February~~May 2831, 2025, our ~~total~~ total operating expenses were $~~101~~141,~~743~~960 compared to $~~490~~660,~~845~~680 for the ~~six~~nine months ended ~~February~~May 2931, 2024, resulting in a decrease of $~~389~~518,~~252~~720. ~~The~~ The decrease is attributable to a ~~total~~ decrease of $~~180~~249,~~985~~998 in general administration, and ~~sales~~ and ~~marketing expenses and~~ a decrease of $~~208~~268,~~267~~722 in research and development expenses. The decrease is due to ~~lack~~a ofreduction ~~funds~~in the company's activities.

We ~~incurred~~realized a financial loss of $221,~~560~~907 for the ~~six~~nine months ended ~~February~~May 2831, 2025, compared to ~~other~~ financial ~~Income~~Loss of $115,~~943~~075 for the ~~six~~nine months ended ~~February~~May 2931, 2024. The increase in financial loss was mainly attributable to interest on converted loans.

~~Net~~We ~~Loss~~incurred capital loss from a realization of equipment of $0 for the nine months ended May 31, 2025, compared to a capital loss of $88,934 for the nine months ended May 31, 2024 incurred form a realization of the Company’s equipment.

~~Net~~As a result, the net loss was $163,867 for the nine ~~six~~ months ended ~~February~~May 2831, ~~2025~~ ~~was $104~~2025,~~140~~ compared to a net loss of $~~503~~634,~~982~~614 for the ~~six~~nine months ended ~~February~~May 2931, 2024~~, for the reasons explained above~~.

13Net loss

Net loss was $163,867 compared to $634,614 for the nine months ended May 31, 2025 and May 31, 2024, The decrease is due to a reduction in the company's activities.

Liquidity and Capital Resources

Overview

As of ~~February~~May 2831, 2025, we had $4513,~~675~~648 in cash ~~compared~~ compared to $26,416 on August 31, 2024. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research ~~and~~ and development expenses, and fees payable to outside medical centers for clinical studies.

Liquidity and Capital Resources during the ~~Six~~nine Months Ended ~~February~~May 2831, ~~2025~~2024 compared to the ~~Six~~nine Months Ended ~~February~~May 2931, 2024

We used cash in operations of $90142,~~741~~760 for the ~~six~~nine months ended ~~February~~May 2831, 2025, compared to cash used in operations of $196,~~244~~019 for the ~~six~~nine months ended ~~February~~May 2931, 2024. The negative ~~cash~~ cash flow from operating activities for the ~~six~~nine months ended ~~February~~May 2831, 2025, is primarily attributable to the Company's net loss from ~~operations~~ operations of $~~104~~163,~~140~~867, offset by convertible loan valuation in a total of $721,~~313,~~479 and an increase in accounts payables and accrued liabilities of $~~6,102~~372.

We had no cash flow from investing activities during the ~~six~~nine months ended ~~February~~May 2831, 2025, compared to cash ~~earned~~flow ~~from~~ investing activities of $18113,~~804~~477 for the ~~six~~nine months ended ~~February 29~~May 31, 2024. The ~~For the six months ended February 29, 2024 the~~ cash flow ~~was~~ from ~~realization~~investing ofactivities ~~equipment~~is ofmainly ~~$20,000~~due ~~off~~to ~~set~~sale ~~by purchase~~ of ~~fixed~~ ~~assets~~equipment ~~in the aggregate amount~~ of $1113,~~196~~477.

We ~~earned~~had cash inflow from financing activities of ~~$110,000~~ ~~for~~129,992 convertible loan during the ~~six~~nine months ended ~~February~~May 2831, 2025, compared to $2426,~~993~~252 convertible loan for the ~~six~~nine months ended ~~February 29~~May 31, 2024. ~~The cash is from convertible loan proceeds.~~

We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.

Going Concern

~~Our~~Due to the uncertainty of our ability to meet our current operating and capital expenses, our independent auditors included an explanatory paragraph in their report on the ~~accompanying unaudited~~ audited financial statements for the year ended August 31, 2024 regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

Our unaudited financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements for the year ended August 31, 2024, included in our Annual Report on Form 10-K as filed on November ~~29th~~30th, 2024, for a discussion of our critical accounting policies and estimates.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The disclosure required under this item is not required to be reported by smaller reporting companies; as such term is defined by Item 503(e) of Regulation S-K.

Item 4. Controls and Procedures.

(a)

Evaluation of Disclosure Controls and Procedures

The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including its Chief Executive Officer, Chief Financial Officer and the full Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company’s disclosure controls and procedures were effective as to this quarterly filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company’s disclosure controls and procedures, as of ~~February~~May ~~28th~~31st, ~~2023~~2024, the end of the period covered by this Quarterly Report on Form 10-Q, were effective to to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the ~~Exchange~~ Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to the Company’s management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.

(b)

Changes in Internal Control over Financial Reporting

Since our annual report, the Company has ~~maintained~~ maintained an Audit Committee to better review our internal financial reporting. There were no other changes in our internal control over ~~financial~~ financial reporting during the period ending ~~February~~May ~~28th~~31, ~~2023~~2025, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

(c)

Limitations on the Effectiveness of Internal Controls

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

1517

PART II- ~~OTHER~~– OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 2. Recent Sale of Unregistered Securities

None.

Item 5. Other Information

During the quarter ended ~~February~~May 2831, 2025, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

Exhibit 31.1*	Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
Exhibit 31.2*	Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).
Exhibit 32.1**	Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.2**	Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS***	~~Inline~~ XBRL Instance Document
101.SCH***	~~Inline~~ XBRL Taxonomy Extension Schema Document
101.CAL***	~~Inline~~ XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF***	~~Inline~~ XBRL Taxonomy Extension Definition Linkbase Document
101.LAB***	~~Inline~~ XBRL Taxonomy Extension Label Linkbase Document
101.PRE***	~~Inline~~ XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

______________________________

*	Filed herewith.

**	Furnished herewith.

***	XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

1618

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CNBX Pharmaceuticals Inc.
Date: April 14, 2025	By:	/s/ Eyal Barad
Date: July 14, 2025	By:	/s/ Eyal Barad
		Eyal Barad
	Title:	Chief Executive Officer (Principal Executive Officer)
Date: April 14, 2025	By:	/s/ Uri Ben Or
Date: July 14, 2025	By:	/s/ Uri Ben Or
		Uri Ben Or
	Title:	Chief Financial Officer (Principal Financial Officer)

1719

Filing Compare · CNBX Pharmaceuticals Inc.